As Josh Johnson slides into the host chair at "The Daily Show" this week, he's riding a viral wave for his stand-up set focused on healing loneliness among men.

Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish technical momentum. Learn more on JNJ stock here.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most undervalued stocks. Johnson & Johnson (NYSE:JNJ) is a global healthcare leader with a diverse portfolio across pharmaceuticals,

Johnson & Johnson halved its expectations for costs this year related to new tariffs and raised its full-year sales and profit forecast on Wednesday after a strong quarter for flagship cancer drug Darzalex and its cardiovascular devices.

The healthcare company's payout currently yields 3.3%, more than double the S&P 500 's ( ^GSPC 0.32%) dividend yield (near a record low at around 1.2%). That high-yielding payout is very healthy, making Johnson & Johnson a very safe way to collect dividend income.

We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ)’s shares are up by 5% since its latest earnings report,

Johnson & Johnson ( ($JNJ) ) has released its Q2 earnings. Here is a breakdown of the information Johnson & Johnson presented to its investors.

Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release. The agreement adds Zilretta, an injectable osteoarthritis treatment, to Johnson & Johnson’s portfolio.